Successful Separation and Stand‑Alone Positioning
Transition services and separation from Owens & Minor are on track; Accendra is now operating as a pure‑play home‑based care company focused on growth and higher margins.
Completed Large Payor Transition with Cash Proceeds
Sold patient service equipment related to the exited large commercial payor for $82 million in cash proceeds, generating a book gain of $52 million (one‑time, excluded from adjusted EBITDA).
Balance Sheet Optimization and Debt Extension
Announced comprehensive balance sheet optimization with lender commitments to: pay off 2027 maturities, extend 2029/2030 notes via exchange offers (new secured notes maturing 2032/2033), and a new $300M revolver due 2030. Expected de‑leveraging of up to ~$115 million and doubling of weighted average debt life to ~5.5 years.
Strong Margin Transformation
Company highlighted a structural transformation from ~19% gross margins and ~4% EBITDA margins pre‑divestiture to nearly 50% gross margins and double‑digit EBITDA margins as a stand‑alone home‑based care business.
Q1 Adjusted EBITDA in Line with Expectations
Reported first quarter adjusted EBITDA of $58 million, consistent with management expectations despite headwinds.
Comfortable Liquidity and Covenant Compliance
Ended the quarter with $337 million cash on the balance sheet, $195 million available on the committed revolver, and in compliance with debt covenants.
Underlying Revenue Growth Excluding Large Payor Impact
Reported total revenue decline of 6.8% for the quarter; excluding the impact of the exited large commercial payor, underlying revenue growth would have been approximately +1%.
Operational Wins in Sleep and Other Categories
Sleep Journey program drove higher revenue per order, lower attrition and improved therapy adherence (adherence improving by single‑digit percentage points quarter‑over‑quarter). Sleep Center of Excellence piloted successfully in 3 markets (nationwide rollout continuing), and category growth included a sleeve category up >4% and home respiratory ~4%; urology and ostomy also led growth.